Profile - To The Moon

nailclipper

Posts · 18Posts · 18
Following · 0Following · 0
Followers · 0Followers · 0

- nailclippernailclipper
  ·2021-07-24
  $UEX Corp.(UEXCF)$gg
  205 Comment
  Like
  Share
  Report
- nailclippernailclipper
  ·2021-06-30
  bullish
  228 Comment
  Like
  Share
  Report
- nailclippernailclipper
  ·2021-06-30
  $UEX Corp.(UEXCF)$wiw
  171 Comment
  Like
  Share
  Report
- nailclippernailclipper
  ·2021-06-29
  https://www.tigerbrokers.com.sg/activity/market/2021/7th-anniversary/*K86S6V-index.html?feature=Banner&Page=Me&lang=en_US&skin=1&edition=fundamental&invite=K86S6V
  Changes in This Year’s Russell Index Rebalancing Are Too Big to Ignore
  The set of FTSE Russell indexes—known most for measuring performance of large cap, small cap, value,
  Changes in This Year’s Russell Index Rebalancing Are Too Big to Ignore
  208 Comment
  Like
  Share
  Report
- nailclippernailclipper
  ·2021-06-29
  wa
  Sorry, this post has been deleted
  270 Comment
  Like
  Share
  Report
- nailclippernailclipper
  ·2021-06-29
  wa
  Sorry, this post has been deleted
  511 Comment
  Like
  Share
  Report
- nailclippernailclipper
  ·2021-06-29
  wa
  4 Dow Stocks Billionaire Money Managers Can't Stop Buying
  Some of the world's most successful money managers have been piling into these well-known businesses.
  4 Dow Stocks Billionaire Money Managers Can't Stop Buying
  220 Comment
  Like
  Share
  Report
- nailclippernailclipper
  ·2021-06-29
  wa
  3 Stocks That Could Make You Much Richer Over the Long Run Than AMC Will
  No, they won't deliver the returns going forward that AMC has so far this year. But neither will AMC.
  3 Stocks That Could Make You Much Richer Over the Long Run Than AMC Will
  231 Comment
  Like
  Share
  Report
- nailclippernailclipper
  ·2021-06-29
  waah
  Meme stocks are blazing hot, once again.
  Meme stocks are blazing hot, once again.CCIV,Workhorse,GameStop,AMC and Bed Bath & Beyond climbed be
  Meme stocks are blazing hot, once again.
  211 Comment
  Like
  Share
  Report
- nailclippernailclipper
  ·2021-06-29
  woah
  CVRx Pursues $100 Million U.S. IPO Plan
  Summary CVRx has filed to raise $100 million in a U.S. IPO of its common stock. The firm is commerc
  CVRx Pursues $100 Million U.S. IPO Plan
  432 1
  2
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3583800505467680","uuid":"3583800505467680","gmtCreate":1620706611201,"gmtModify":1624847373803,"name":"nailclipper","pinyin":"nailclipper","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/0dd7f7188273b9053103027e7b842d3d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":3,"tweetSize":18,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":174641708,"gmtCreate":1627097454104,"gmtModify":1703484221912,"author":{"id":"3583800505467680","authorId":"3583800505467680","name":"nailclipper","avatar":"https://static.tigerbbs.com/0dd7f7188273b9053103027e7b842d3d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583800505467680","idStr":"3583800505467680"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/UEXCF\">$UEX Corp.(UEXCF)$</a>gg","listText":"<a href=\"https://laohu8.com/S/UEXCF\">$UEX Corp.(UEXCF)$</a>gg","text":"$UEX Corp.(UEXCF)$gg","images":[{"img":"https://static.tigerbbs.com/11c94098dca042253950fa7972fcb17a","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/174641708","isVote":1,"tweetType":1,"viewCount":205,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":151087291,"gmtCreate":1625058134813,"gmtModify":1703735019086,"author":{"id":"3583800505467680","authorId":"3583800505467680","name":"nailclipper","avatar":"https://static.tigerbbs.com/0dd7f7188273b9053103027e7b842d3d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583800505467680","idStr":"3583800505467680"},"themes":[],"htmlText":"bullish","listText":"bullish","text":"bullish","images":[{"img":"https://static.tigerbbs.com/c4b4a548c1b0231df82220d7e791baf8","width":"1080","height":"2872"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/151087291","isVote":1,"tweetType":1,"viewCount":228,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":151084700,"gmtCreate":1625058107400,"gmtModify":1703735017934,"author":{"id":"3583800505467680","authorId":"3583800505467680","name":"nailclipper","avatar":"https://static.tigerbbs.com/0dd7f7188273b9053103027e7b842d3d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583800505467680","idStr":"3583800505467680"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/UEXCF\">$UEX Corp.(UEXCF)$</a>wiw","listText":"<a href=\"https://laohu8.com/S/UEXCF\">$UEX Corp.(UEXCF)$</a>wiw","text":"$UEX Corp.(UEXCF)$wiw","images":[{"img":"https://static.tigerbbs.com/087a0f7bbf32e98d3a18b6db4d99e19b","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/151084700","isVote":1,"tweetType":1,"viewCount":171,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":159924855,"gmtCreate":1624937433977,"gmtModify":1703848378187,"author":{"id":"3583800505467680","authorId":"3583800505467680","name":"nailclipper","avatar":"https://static.tigerbbs.com/0dd7f7188273b9053103027e7b842d3d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583800505467680","idStr":"3583800505467680"},"themes":[],"htmlText":"https://www.tigerbrokers.com.sg/activity/market/2021/7th-anniversary/*K86S6V-index.html?feature=Banner&amp;Page=Me&amp;lang=en_US&amp;skin=1&amp;edition=fundamental&amp;invite=K86S6V","listText":"https://www.tigerbrokers.com.sg/activity/market/2021/7th-anniversary/*K86S6V-index.html?feature=Banner&amp;Page=Me&amp;lang=en_US&amp;skin=1&amp;edition=fundamental&amp;invite=K86S6V","text":"https://www.tigerbrokers.com.sg/activity/market/2021/7th-anniversary/*K86S6V-index.html?feature=Banner&Page=Me&lang=en_US&skin=1&edition=fundamental&invite=K86S6V","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159924855","repostId":"1101350966","repostType":4,"repost":{"id":"1101350966","pubTimestamp":1624862779,"share":"https://ttm.financial/m/news/1101350966?lang=&edition=fundamental","pubTime":"2021-06-28 14:46","market":"us","language":"en","title":"Changes in This Year’s Russell Index Rebalancing Are Too Big to Ignore","url":"https://stock-news.laohu8.com/highlight/detail?id=1101350966","media":"Barrons","summary":"The set of FTSE Russell indexes—known most for measuring performance of large cap, small cap, value,","content":"<p>The set of FTSE Russell indexes—known most for measuring performance of large cap, small cap, value, and growth segments of the market—are rebalanced every year and for most investors it’s a non-event.</p>\n<p>If they take interest, it is mainly to see which stocks may gain or lose in terms of cash flows because they were added or dropped from a particular index. (This year&nbsp;GameStop&nbsp;is graduating&nbsp;to the large-cap Russell 1000 index, but&nbsp;AMC&nbsp;isn’t, for example).</p>\n<p>But for financial advisors who spend time on portfolio construction and need to benchmark their asset allocation decisions using these indexes, this year’s reconstitution could be a game changer. That’s mainly because market caps have grown so significantly in the past year.</p>\n<p>In fact, all advisors, even those who use model portfolios, should make sure they are conversant in these seismic market shifts:</p>\n<ul>\n <li><b>The total U.S. stock market is much bigger.</b>If you used $30 trillion as a rounding number, you’re now off by almost $20 trillion. According to Russell, the total U.S. equity market capitalization increased by 52% to nearly $48 trillion, as of May 2021. That’s up from $31 trillion in 2020.</li>\n <li><b>Large cap stocks are much larger (so are small-cap stocks).</b>If you think $1 billion in market cap makes a large-cap, you’re off by a few billion. As of this year, the market cap breakpoint separating the small-caps in the Russell 2000 Index and the large-caps in the Russell 1000 Index increased to $5.2 billion. That’s up from $3.0 billion in 2020—a massive 73% jump. Another sign of the times: The smallest company in the index is&nbsp;Velocity Financial&nbsp;with a market cap of $257 million. Last year’s smallest, Limestone Bancorp, had a market cap of $95 million.</li>\n <li><b>Even megacap stocks are bigger than you might think.</b>$200 billion in market cap doesn’t really constitute a megacap anymore. There are now four companies with more than a $1 trillion market cap. This year&nbsp;Alphabet&nbsp;joined&nbsp;Microsoft,Apple&nbsp;and&nbsp;Amazon,which reached the trillion mark in 2020.</li>\n <li><b>Yes, value really is outperforming growth.</b>But it’s more pronounced among smaller companies, according to Russell. The 2000 Value Index returned 79% compared to 50% for the Russell 2000 Growth through May. Looking just at large caps, the Russell 1000 Value had a total return of 44% versus the Russell 1000 Growth at 40%.</li>\n <li><b>Sectors are shifting.</b>For the large-cap Russell 1000, the sector shifts are relatively minor. Technology and consumer discretionary weights increased modestly. For the Russell 2000 Index, the most notable increase is in health care, while consumer discretionary decreased. Of the 43 IPOs added to the Russell 3000, about half are health care companies.</li>\n</ul>\n<p>Advisors who invest using passive index investing products (direct indexing is growing&nbsp;in popularity) should note changes to the index composition, as well as advisors who use indexes to benchmark success of active managers.</p>\n<p>“You need to make sure indexes are truly representative” of market segments, says Hilary Keitel, head of U.S. Wealth for FTSE Russell. “This allows financial advisors to fulfill a more precise asset allocation.”</p>\n<p>Russell spreads out the reconstitution over a month so broad market impact is limited. The first official Russell index lists were announced June 4. Indexes are scheduled for their 2021 reconstitution after the market closes on June 25. All additions and deletions are on the&nbsp;FTSE Russell website.</p>\n<p>Changes will impact more than $10.6 trillion in investor assets. “We anticipate this to be one of the largest trading days of the year in the U.S. markets,” says Catherine Yoshimoto, director of product management at FTSE Russell. “ETF product issuers keep a close eye on this,” she says. They aren’t the only ones.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Changes in This Year’s Russell Index Rebalancing Are Too Big to Ignore</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChanges in This Year’s Russell Index Rebalancing Are Too Big to Ignore\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-28 14:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/changes-in-this-years-russell-index-rebalancing-are-too-big-to-ignore-51624310730?mod=hp_DAY_Theme_1_3><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The set of FTSE Russell indexes—known most for measuring performance of large cap, small cap, value, and growth segments of the market—are rebalanced every year and for most investors it’s a non-event...</p>\n\n<a href=\"https://www.barrons.com/articles/changes-in-this-years-russell-index-rebalancing-are-too-big-to-ignore-51624310730?mod=hp_DAY_Theme_1_3\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.barrons.com/articles/changes-in-this-years-russell-index-rebalancing-are-too-big-to-ignore-51624310730?mod=hp_DAY_Theme_1_3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101350966","content_text":"The set of FTSE Russell indexes—known most for measuring performance of large cap, small cap, value, and growth segments of the market—are rebalanced every year and for most investors it’s a non-event.\nIf they take interest, it is mainly to see which stocks may gain or lose in terms of cash flows because they were added or dropped from a particular index. (This year GameStop is graduating to the large-cap Russell 1000 index, but AMC isn’t, for example).\nBut for financial advisors who spend time on portfolio construction and need to benchmark their asset allocation decisions using these indexes, this year’s reconstitution could be a game changer. That’s mainly because market caps have grown so significantly in the past year.\nIn fact, all advisors, even those who use model portfolios, should make sure they are conversant in these seismic market shifts:\n\nThe total U.S. stock market is much bigger.If you used $30 trillion as a rounding number, you’re now off by almost $20 trillion. According to Russell, the total U.S. equity market capitalization increased by 52% to nearly $48 trillion, as of May 2021. That’s up from $31 trillion in 2020.\nLarge cap stocks are much larger (so are small-cap stocks).If you think $1 billion in market cap makes a large-cap, you’re off by a few billion. As of this year, the market cap breakpoint separating the small-caps in the Russell 2000 Index and the large-caps in the Russell 1000 Index increased to $5.2 billion. That’s up from $3.0 billion in 2020—a massive 73% jump. Another sign of the times: The smallest company in the index is Velocity Financial with a market cap of $257 million. Last year’s smallest, Limestone Bancorp, had a market cap of $95 million.\nEven megacap stocks are bigger than you might think.$200 billion in market cap doesn’t really constitute a megacap anymore. There are now four companies with more than a $1 trillion market cap. This year Alphabet joined Microsoft,Apple and Amazon,which reached the trillion mark in 2020.\nYes, value really is outperforming growth.But it’s more pronounced among smaller companies, according to Russell. The 2000 Value Index returned 79% compared to 50% for the Russell 2000 Growth through May. Looking just at large caps, the Russell 1000 Value had a total return of 44% versus the Russell 1000 Growth at 40%.\nSectors are shifting.For the large-cap Russell 1000, the sector shifts are relatively minor. Technology and consumer discretionary weights increased modestly. For the Russell 2000 Index, the most notable increase is in health care, while consumer discretionary decreased. Of the 43 IPOs added to the Russell 3000, about half are health care companies.\n\nAdvisors who invest using passive index investing products (direct indexing is growing in popularity) should note changes to the index composition, as well as advisors who use indexes to benchmark success of active managers.\n“You need to make sure indexes are truly representative” of market segments, says Hilary Keitel, head of U.S. Wealth for FTSE Russell. “This allows financial advisors to fulfill a more precise asset allocation.”\nRussell spreads out the reconstitution over a month so broad market impact is limited. The first official Russell index lists were announced June 4. Indexes are scheduled for their 2021 reconstitution after the market closes on June 25. All additions and deletions are on the FTSE Russell website.\nChanges will impact more than $10.6 trillion in investor assets. “We anticipate this to be one of the largest trading days of the year in the U.S. markets,” says Catherine Yoshimoto, director of product management at FTSE Russell. “ETF product issuers keep a close eye on this,” she says. They aren’t the only ones.","news_type":1},"isVote":1,"tweetType":1,"viewCount":208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159928987,"gmtCreate":1624937167049,"gmtModify":1703848372948,"author":{"id":"3583800505467680","authorId":"3583800505467680","name":"nailclipper","avatar":"https://static.tigerbbs.com/0dd7f7188273b9053103027e7b842d3d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583800505467680","idStr":"3583800505467680"},"themes":[],"htmlText":"wa","listText":"wa","text":"wa","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159928987","repostId":"2146900754","repostType":4,"isVote":1,"tweetType":1,"viewCount":270,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159928058,"gmtCreate":1624937150274,"gmtModify":1703848372624,"author":{"id":"3583800505467680","authorId":"3583800505467680","name":"nailclipper","avatar":"https://static.tigerbbs.com/0dd7f7188273b9053103027e7b842d3d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583800505467680","idStr":"3583800505467680"},"themes":[],"htmlText":"wa","listText":"wa","text":"wa","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159928058","repostId":"1164912248","repostType":4,"isVote":1,"tweetType":1,"viewCount":511,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159921680,"gmtCreate":1624937136140,"gmtModify":1703848371815,"author":{"id":"3583800505467680","authorId":"3583800505467680","name":"nailclipper","avatar":"https://static.tigerbbs.com/0dd7f7188273b9053103027e7b842d3d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583800505467680","idStr":"3583800505467680"},"themes":[],"htmlText":"wa","listText":"wa","text":"wa","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159921680","repostId":"2146877158","repostType":4,"repost":{"id":"2146877158","pubTimestamp":1624879777,"share":"https://ttm.financial/m/news/2146877158?lang=&edition=fundamental","pubTime":"2021-06-28 19:29","market":"us","language":"en","title":"4 Dow Stocks Billionaire Money Managers Can't Stop Buying","url":"https://stock-news.laohu8.com/highlight/detail?id=2146877158","media":"Motley Fool","summary":"Some of the world's most successful money managers have been piling into these well-known businesses.","content":"<p>For more than 125 years, the <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has been <a href=\"https://laohu8.com/S/AONE\">one</a> of the most widely followed stock indexes in the world. Though far from perfect -- it's a price-weighted index instead of market cap-weighted -- the Dow Jones is comprised of 30 time-tested and successful multinational companies that have helped lead it higher.</p>\n<p>Given the long-tenured success of its components, we shouldn't be surprised to see billionaire money managers putting their money to work in Dow components. In particular, billionaires can't stop buying the following four Dow stocks, based on Form 13F filings with the Securities and Exchange Commission for the first quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2e4fd91ccb7d74ef87a77081ef701b59\" tg-width=\"700\" tg-height=\"486\"><span>Image source: Getty Images.</span></p>\n<h2>Microsoft</h2>\n<p>Last week, <b>Microsoft</b> (NASDAQ:MSFT) entered a very exclusive club: It became only the second publicly traded company to surpass a $2 trillion market cap, along with <b>Apple</b>. But its rising valuation hasn't deterred billionaires. Larry Fink's <b>BlackRock</b>, Chase Coleman's Tiger Global Management, and Jeff Yass's Susquehanna International respectively scooped up 3.14 million shares, 1.83 million shares, and 1.81 million shares in the first quarter. For Susquehanna, it more than doubled the company's previous stake.</p>\n<p>The fascination with Microsoft boils down to three factors. First, there's a lot of excitement surrounding Old Softy's push into the cloud. Cloud infrastructure service Azure grew sales by 50% in the March-ended quarter, with most of the company's other cloud-based segments (Office commercial, Dynamics, and Windows) increasing their sales by double-digits.</p>\n<p>Second, Microsoft's legacy operations are still cash cows. Even though Windows and Office aren't the insane growth stories they once were, Windows remains the dominant operating platform for PCs. These may be slower-growing segments, but the margins remain robust.</p>\n<p>Third and finally, Microsoft's large cash pile and abundant cash flow afford it the opportunity to lean on inorganic growth opportunities. Though not all acquisitions will be winners, a few home runs is all it takes for Microsoft to keep up its double-digit growth rate.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b13f98298635a74f4491a99bf47eeded\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/WBA\">Walgreens Boots Alliance</a></h2>\n<p>Another Dow stock that has the full attention of billionaire money managers is pharmacy chain <b>Walgreens Boots Alliance</b> (NASDAQ:WBA). The company with the smallest influence within the Dow saw BlackRock buy 6.91 million shares in Q1 2021. Additionally, Ole Andreas Havlorsen's Viking Global added 1.72 million shares, while Jim Simons' Renaissance Technologies added 211,000 shares.</p>\n<p>Why Walgreens? The answer is that we're on the cusp of seeing the company's multipoint turnaround plan take shape. Management expects more than $2 billion in annual cost savings by fiscal 2022, but has also been aggressively reinvesting in digitization efforts. A beefed up online presence has an opportunity to really jump-start Walgreens' top-line growth.</p>\n<p>Perhaps more exciting is Walgreens partnering up with VillageMD. The duo aims to open up to 700 full-service clinics throughout the United States. Whereas most health clinics inside pharmacy chains can't handle more than a vaccine or sniffle, Walgreens' focus on full-service treatment is aimed at drawing in patients with chronic illnesses. Let's not forget that Walgreens' pharmacy is its top-tier margin driver. This partnership should help improve brand loyalty and could funnel more prescriptions to its pharmacies.</p>\n<p>Furthermore, Walgreens remains relatively inexpensive. Despite the <b>S&amp;P 500</b>'s Shiller price-to-earnings ratio nearing a two-decade high, shares of Walgreens Boots Alliance can be nabbed for a very reasonable 10 times Wall Street's consensus earnings for next year.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8db519446ea812ab6b8023df3f60f0c3\" tg-width=\"700\" tg-height=\"393\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/IBM\">IBM</a></h2>\n<p>Given its nearly decade-long underperformance, this may come a shock, but <b>IBM</b> (NYSE:IBM) -- <i>yes</i>, IBM -- has been an extremely popular buy among billionaire money managers. BlackRock, Renaissance Technologies, Susquehanna, and Ken Griffin's Citadel Advisors, respectively purchased 2.01 million shares, 1.11 million shares, 147,000 shares, and 198,000 shares during the first quarter.</p>\n<p>For years, the issue with IBM was its delayed entrance into cloud computing. Relying on hardware and static software was highly profitable for a long time. But beginning in the early 2010s, it became a drag for Big Blue, leading to a multiyear sales decline. The good news is that, through internal innovation and a series of acquisitions, IBM's growth engine looks to be headed in the right direction, once again.</p>\n<p>With a renewed focus on hybrid cloud services, IBM has an opportunity to become a major player in big-data processing. Its hybrid cloud solutions are also particularly useful in a work environment that's become increasingly mobile and remote. During the March-ended quarter, IBM's cloud revenue jumped 21% from the prior-year period, and it accounted for 37% of total sales.</p>\n<p>Another factor that tends to get overlooked is IBM has done an excellent job of tapering expenses at its legacy operations to preserve margins and cash flow. Though these are generally stagnant operating segments, margins have been flat or rising. This gives IBM more capital to make acquisitions and pay its juicy 4.5% dividend yield.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/07a7199c92cdbda4868c801c72e43aa1\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon Communications</h2>\n<p>The final Dow stock billionaire money managers can't stop buying is arguably the least volatile component within the iconic index: <b>Verizon</b> (NYSE:VZ). During the first quarter, Warren Buffett's <b>Berkshire Hathaway</b>&nbsp;gobbled up 12.11 million shares, BlackRock added 6.62 million shares, and Susquehanna almost tripled its stake by purchasing 3.36 million shares.</p>\n<p>The reason billionaires are buying likely boils down to two factors. First, Verizon may well be the safest high-yield dividend stock on the planet. The wireless services it provides generates highly predictable cash flow. With minimal volatility and a 4.5% yield, it appears to be a far more attractive place for institutional investors to park their cash than just leaving it under the proverbial mattress.</p>\n<p>The other factor here is that Verizon does have two organic growth catalysts working in its favor. The bigger of the two is the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds have improved, which means we should see a multiyear tech upgrade cycle for businesses and consumers. Because Verizon generates healthy margins from wireless data consumption, its investments in 5G should pay off handsomely.</p>\n<p>Verizon also acquired 5G midband spectrum that'll it be using to grow its in-home broadband offerings. By 2023, the company is aiming for 30 million residential broadband customers.</p>\n<p>Verizon will never be the growth stock it once was, but it has <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the safest floors of any publicly traded company.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Dow Stocks Billionaire Money Managers Can't Stop Buying</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Dow Stocks Billionaire Money Managers Can't Stop Buying\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-28 19:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/4-dow-stocks-billionaire-money-managers-are-buying/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For more than 125 years, the Dow Jones Industrial Average (DJINDICES:^DJI) has been one of the most widely followed stock indexes in the world. Though far from perfect -- it's a price-weighted index ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/4-dow-stocks-billionaire-money-managers-are-buying/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WBA":"沃尔格林联合博姿","VZ":"威瑞森","IBM":"IBM","MSFT":"微软"},"source_url":"https://www.fool.com/investing/2021/06/28/4-dow-stocks-billionaire-money-managers-are-buying/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146877158","content_text":"For more than 125 years, the Dow Jones Industrial Average (DJINDICES:^DJI) has been one of the most widely followed stock indexes in the world. Though far from perfect -- it's a price-weighted index instead of market cap-weighted -- the Dow Jones is comprised of 30 time-tested and successful multinational companies that have helped lead it higher.\nGiven the long-tenured success of its components, we shouldn't be surprised to see billionaire money managers putting their money to work in Dow components. In particular, billionaires can't stop buying the following four Dow stocks, based on Form 13F filings with the Securities and Exchange Commission for the first quarter.\nImage source: Getty Images.\nMicrosoft\nLast week, Microsoft (NASDAQ:MSFT) entered a very exclusive club: It became only the second publicly traded company to surpass a $2 trillion market cap, along with Apple. But its rising valuation hasn't deterred billionaires. Larry Fink's BlackRock, Chase Coleman's Tiger Global Management, and Jeff Yass's Susquehanna International respectively scooped up 3.14 million shares, 1.83 million shares, and 1.81 million shares in the first quarter. For Susquehanna, it more than doubled the company's previous stake.\nThe fascination with Microsoft boils down to three factors. First, there's a lot of excitement surrounding Old Softy's push into the cloud. Cloud infrastructure service Azure grew sales by 50% in the March-ended quarter, with most of the company's other cloud-based segments (Office commercial, Dynamics, and Windows) increasing their sales by double-digits.\nSecond, Microsoft's legacy operations are still cash cows. Even though Windows and Office aren't the insane growth stories they once were, Windows remains the dominant operating platform for PCs. These may be slower-growing segments, but the margins remain robust.\nThird and finally, Microsoft's large cash pile and abundant cash flow afford it the opportunity to lean on inorganic growth opportunities. Though not all acquisitions will be winners, a few home runs is all it takes for Microsoft to keep up its double-digit growth rate.\nImage source: Getty Images.\nWalgreens Boots Alliance\nAnother Dow stock that has the full attention of billionaire money managers is pharmacy chain Walgreens Boots Alliance (NASDAQ:WBA). The company with the smallest influence within the Dow saw BlackRock buy 6.91 million shares in Q1 2021. Additionally, Ole Andreas Havlorsen's Viking Global added 1.72 million shares, while Jim Simons' Renaissance Technologies added 211,000 shares.\nWhy Walgreens? The answer is that we're on the cusp of seeing the company's multipoint turnaround plan take shape. Management expects more than $2 billion in annual cost savings by fiscal 2022, but has also been aggressively reinvesting in digitization efforts. A beefed up online presence has an opportunity to really jump-start Walgreens' top-line growth.\nPerhaps more exciting is Walgreens partnering up with VillageMD. The duo aims to open up to 700 full-service clinics throughout the United States. Whereas most health clinics inside pharmacy chains can't handle more than a vaccine or sniffle, Walgreens' focus on full-service treatment is aimed at drawing in patients with chronic illnesses. Let's not forget that Walgreens' pharmacy is its top-tier margin driver. This partnership should help improve brand loyalty and could funnel more prescriptions to its pharmacies.\nFurthermore, Walgreens remains relatively inexpensive. Despite the S&P 500's Shiller price-to-earnings ratio nearing a two-decade high, shares of Walgreens Boots Alliance can be nabbed for a very reasonable 10 times Wall Street's consensus earnings for next year.\nImage source: Getty Images.\nIBM\nGiven its nearly decade-long underperformance, this may come a shock, but IBM (NYSE:IBM) -- yes, IBM -- has been an extremely popular buy among billionaire money managers. BlackRock, Renaissance Technologies, Susquehanna, and Ken Griffin's Citadel Advisors, respectively purchased 2.01 million shares, 1.11 million shares, 147,000 shares, and 198,000 shares during the first quarter.\nFor years, the issue with IBM was its delayed entrance into cloud computing. Relying on hardware and static software was highly profitable for a long time. But beginning in the early 2010s, it became a drag for Big Blue, leading to a multiyear sales decline. The good news is that, through internal innovation and a series of acquisitions, IBM's growth engine looks to be headed in the right direction, once again.\nWith a renewed focus on hybrid cloud services, IBM has an opportunity to become a major player in big-data processing. Its hybrid cloud solutions are also particularly useful in a work environment that's become increasingly mobile and remote. During the March-ended quarter, IBM's cloud revenue jumped 21% from the prior-year period, and it accounted for 37% of total sales.\nAnother factor that tends to get overlooked is IBM has done an excellent job of tapering expenses at its legacy operations to preserve margins and cash flow. Though these are generally stagnant operating segments, margins have been flat or rising. This gives IBM more capital to make acquisitions and pay its juicy 4.5% dividend yield.\nImage source: Getty Images.\nVerizon Communications\nThe final Dow stock billionaire money managers can't stop buying is arguably the least volatile component within the iconic index: Verizon (NYSE:VZ). During the first quarter, Warren Buffett's Berkshire Hathaway gobbled up 12.11 million shares, BlackRock added 6.62 million shares, and Susquehanna almost tripled its stake by purchasing 3.36 million shares.\nThe reason billionaires are buying likely boils down to two factors. First, Verizon may well be the safest high-yield dividend stock on the planet. The wireless services it provides generates highly predictable cash flow. With minimal volatility and a 4.5% yield, it appears to be a far more attractive place for institutional investors to park their cash than just leaving it under the proverbial mattress.\nThe other factor here is that Verizon does have two organic growth catalysts working in its favor. The bigger of the two is the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds have improved, which means we should see a multiyear tech upgrade cycle for businesses and consumers. Because Verizon generates healthy margins from wireless data consumption, its investments in 5G should pay off handsomely.\nVerizon also acquired 5G midband spectrum that'll it be using to grow its in-home broadband offerings. By 2023, the company is aiming for 30 million residential broadband customers.\nVerizon will never be the growth stock it once was, but it has one of the safest floors of any publicly traded company.","news_type":1},"isVote":1,"tweetType":1,"viewCount":220,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159921037,"gmtCreate":1624937122629,"gmtModify":1703848370839,"author":{"id":"3583800505467680","authorId":"3583800505467680","name":"nailclipper","avatar":"https://static.tigerbbs.com/0dd7f7188273b9053103027e7b842d3d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583800505467680","idStr":"3583800505467680"},"themes":[],"htmlText":"wa","listText":"wa","text":"wa","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159921037","repostId":"2146983887","repostType":4,"repost":{"id":"2146983887","pubTimestamp":1624886639,"share":"https://ttm.financial/m/news/2146983887?lang=&edition=fundamental","pubTime":"2021-06-28 21:23","market":"us","language":"en","title":"3 Stocks That Could Make You Much Richer Over the Long Run Than AMC Will","url":"https://stock-news.laohu8.com/highlight/detail?id=2146983887","media":"Motley Fool","summary":"No, they won't deliver the returns going forward that AMC has so far this year. But neither will AMC.","content":"<p>If you'd invested $10,000 in&nbsp;<b>AMC Entertainment</b> (NYSE:AMC) roughly six months ago, you'd have more than $250,000 right now. That's a staggering return that any investor would love to make.</p>\n<p>However, there's something important to consider before buying AMC stock right now: Investing is focused on the future, not the past. Shares of the movie theater chain aren't going to generate those kinds of gains going forward. If they did, AMC would soon be more than three times bigger than <b>Apple</b>. That's extremely unlikely, to say the least.</p>\n<p>Still, it's possible that AMC will continue performing well (albeit not anywhere near its recent levels) over the next year or two as moviegoers return to theaters. The stock has made some investors quite wealthy over the last few months. But here are three stocks that could make you much richer over the long term than AMC will.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9cf5e28ce06825d2bfd9ebed7c7a4d8f\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Etsy</h2>\n<p><b>Etsy</b>'s (NASDAQ:ETSY) market cap of $23 billion is well below AMC's market cap of close to $29 billion. I'd argue that the popular e-commerce company has a much greater long-term opportunity than AMC does, though.</p>\n<p>First of all, Etsy practically owns the niche online market in personalized handcrafted goods. Others have attempted to beat the company on its own turf but have failed. There are still significant growth opportunities in this $250 billion annual market.</p>\n<p>However, the pandemic showed Etsy more than ever that it can compete in a larger arena. The company now thinks that its total addressable market is close to $1.7 trillion.</p>\n<p>One way that Etsy is going after this expanded market is through acquisitions. Most recently, the company announced plans to acquire Depop for $1.6 billion, a move that vaults Etsy into the clothing resale business.</p>\n<p>I think that Etsy is a stock that could be a 10-bagger over the long run. The odds of AMC having that level of gains going forward are slim.</p>\n<h2>Innovative Industrial Properties</h2>\n<p>Speaking of big market opportunities, the U.S. medical cannabis market is growing by leaps and bounds. So far, 36 states have legalized medical cannabis.&nbsp;<b>Innovative Industrial Properties</b> (NYSE:IIPR) stands out as a key beneficiary from this growth.</p>\n<p>The company is the leading real estate investment trust (REIT) focused on the medical cannabis industry. IIP's forte is sale-leaseback transactions. In these deals, the REIT buys properties from cannabis operators. The operators then lease the properties back with a long-term lease agreement.</p>\n<p>Over the last three years, IIP's revenue has soared 1,300%. Its profits have skyrocketed more than 2,200%. Investors have also made even more money from the company's dividends.</p>\n<p>IIP currently owns 72 properties in 18 states. It should be able to continue growing briskly by making more sale-leaseback deals in those states (which include several of the biggest medical cannabis markets in the U.S.) as well as expanding into additional states.</p>\n<h2>Intuitive Surgical</h2>\n<p>I recently wrote about my top stock to buy in June. My pick was robotic surgical systems pioneer <b>Intuitive Surgical</b> (NASDAQ:ISRG).</p>\n<p>Like AMC, Intuitive Surgical is a reopening play. Just as the COVID-19 pandemic shut down theaters, it also significantly impacted the volumes of non-emergency surgical procedures. Intuitive generates most of its revenue from selling replacement instruments and accessories for its da Vinci robotic surgical systems. Lower numbers of procedures meant lower revenue for the company.</p>\n<p>Prior to the pandemic, the number of movie tickets sold was declining. That's a not-so-great trend for AMC that could rear its ugly head again after a rebound in 2021 and 2022. Intuitive's procedure volume, though, has risen steadily for quite a while. Even with the pandemic, procedures still increased 1% year over year in 2020.</p>\n<p>Intuitive's long-term prospects are the main reason why I like this stock, though. The company has a huge growth opportunity targeting the procedures where it already has regulatory clearances. Even better, Intuitive thinks that it can more than triple its current addressable market by launching new products and securing additional regulatory clearances.</p>\n<p>Sure, Intuitive Surgical is already a big company with a market cap of over $100 billion. I think that it will be able to become a much larger company over the next decade and make investors who buy and hold the stock a lot of money.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Make You Much Richer Over the Long Run Than AMC Will</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Make You Much Richer Over the Long Run Than AMC Will\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-28 21:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/28/3-stocks-make-you-richer-long-term-than-amc/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you'd invested $10,000 in AMC Entertainment (NYSE:AMC) roughly six months ago, you'd have more than $250,000 right now. That's a staggering return that any investor would love to make.\nHowever, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/28/3-stocks-make-you-richer-long-term-than-amc/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ETSY":"Etsy, Inc.","ISRG":"直觉外科公司","IIPR":"Innovative Industrial Properties Inc"},"source_url":"https://www.fool.com/investing/2021/06/28/3-stocks-make-you-richer-long-term-than-amc/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146983887","content_text":"If you'd invested $10,000 in AMC Entertainment (NYSE:AMC) roughly six months ago, you'd have more than $250,000 right now. That's a staggering return that any investor would love to make.\nHowever, there's something important to consider before buying AMC stock right now: Investing is focused on the future, not the past. Shares of the movie theater chain aren't going to generate those kinds of gains going forward. If they did, AMC would soon be more than three times bigger than Apple. That's extremely unlikely, to say the least.\nStill, it's possible that AMC will continue performing well (albeit not anywhere near its recent levels) over the next year or two as moviegoers return to theaters. The stock has made some investors quite wealthy over the last few months. But here are three stocks that could make you much richer over the long term than AMC will.\nImage source: Getty Images.\nEtsy\nEtsy's (NASDAQ:ETSY) market cap of $23 billion is well below AMC's market cap of close to $29 billion. I'd argue that the popular e-commerce company has a much greater long-term opportunity than AMC does, though.\nFirst of all, Etsy practically owns the niche online market in personalized handcrafted goods. Others have attempted to beat the company on its own turf but have failed. There are still significant growth opportunities in this $250 billion annual market.\nHowever, the pandemic showed Etsy more than ever that it can compete in a larger arena. The company now thinks that its total addressable market is close to $1.7 trillion.\nOne way that Etsy is going after this expanded market is through acquisitions. Most recently, the company announced plans to acquire Depop for $1.6 billion, a move that vaults Etsy into the clothing resale business.\nI think that Etsy is a stock that could be a 10-bagger over the long run. The odds of AMC having that level of gains going forward are slim.\nInnovative Industrial Properties\nSpeaking of big market opportunities, the U.S. medical cannabis market is growing by leaps and bounds. So far, 36 states have legalized medical cannabis. Innovative Industrial Properties (NYSE:IIPR) stands out as a key beneficiary from this growth.\nThe company is the leading real estate investment trust (REIT) focused on the medical cannabis industry. IIP's forte is sale-leaseback transactions. In these deals, the REIT buys properties from cannabis operators. The operators then lease the properties back with a long-term lease agreement.\nOver the last three years, IIP's revenue has soared 1,300%. Its profits have skyrocketed more than 2,200%. Investors have also made even more money from the company's dividends.\nIIP currently owns 72 properties in 18 states. It should be able to continue growing briskly by making more sale-leaseback deals in those states (which include several of the biggest medical cannabis markets in the U.S.) as well as expanding into additional states.\nIntuitive Surgical\nI recently wrote about my top stock to buy in June. My pick was robotic surgical systems pioneer Intuitive Surgical (NASDAQ:ISRG).\nLike AMC, Intuitive Surgical is a reopening play. Just as the COVID-19 pandemic shut down theaters, it also significantly impacted the volumes of non-emergency surgical procedures. Intuitive generates most of its revenue from selling replacement instruments and accessories for its da Vinci robotic surgical systems. Lower numbers of procedures meant lower revenue for the company.\nPrior to the pandemic, the number of movie tickets sold was declining. That's a not-so-great trend for AMC that could rear its ugly head again after a rebound in 2021 and 2022. Intuitive's procedure volume, though, has risen steadily for quite a while. Even with the pandemic, procedures still increased 1% year over year in 2020.\nIntuitive's long-term prospects are the main reason why I like this stock, though. The company has a huge growth opportunity targeting the procedures where it already has regulatory clearances. Even better, Intuitive thinks that it can more than triple its current addressable market by launching new products and securing additional regulatory clearances.\nSure, Intuitive Surgical is already a big company with a market cap of over $100 billion. I think that it will be able to become a much larger company over the next decade and make investors who buy and hold the stock a lot of money.","news_type":1},"isVote":1,"tweetType":1,"viewCount":231,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159923558,"gmtCreate":1624937111474,"gmtModify":1703848370678,"author":{"id":"3583800505467680","authorId":"3583800505467680","name":"nailclipper","avatar":"https://static.tigerbbs.com/0dd7f7188273b9053103027e7b842d3d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583800505467680","idStr":"3583800505467680"},"themes":[],"htmlText":"waah","listText":"waah","text":"waah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159923558","repostId":"1148481357","repostType":4,"repost":{"id":"1148481357","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624888651,"share":"https://ttm.financial/m/news/1148481357?lang=&edition=fundamental","pubTime":"2021-06-28 21:57","market":"us","language":"en","title":"Meme stocks are blazing hot, once again.","url":"https://stock-news.laohu8.com/highlight/detail?id=1148481357","media":"Tiger Newspress","summary":"Meme stocks are blazing hot, once again.CCIV,Workhorse,GameStop,AMC and Bed Bath & Beyond climbed be","content":"<p>Meme stocks are blazing hot, once again.CCIV,Workhorse,GameStop,AMC and Bed Bath &amp; Beyond climbed between 5% and 7%.</p>\n<p><img src=\"https://static.tigerbbs.com/fb2694f87fdac29278fbf2a583a1bf36\" tg-width=\"390\" tg-height=\"743\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meme stocks are blazing hot, once again.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeme stocks are blazing hot, once again.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-28 21:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Meme stocks are blazing hot, once again.CCIV,Workhorse,GameStop,AMC and Bed Bath &amp; Beyond climbed between 5% and 7%.</p>\n<p><img src=\"https://static.tigerbbs.com/fb2694f87fdac29278fbf2a583a1bf36\" tg-width=\"390\" tg-height=\"743\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线","WKHS":"Workhorse Group, Inc.","GME":"游戏驿站","BBBY":"3B家居"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148481357","content_text":"Meme stocks are blazing hot, once again.CCIV,Workhorse,GameStop,AMC and Bed Bath & Beyond climbed between 5% and 7%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":211,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159929542,"gmtCreate":1624937039786,"gmtModify":1703848368893,"author":{"id":"3583800505467680","authorId":"3583800505467680","name":"nailclipper","avatar":"https://static.tigerbbs.com/0dd7f7188273b9053103027e7b842d3d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583800505467680","idStr":"3583800505467680"},"themes":[],"htmlText":"woah","listText":"woah","text":"woah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/159929542","repostId":"1124906464","repostType":4,"repost":{"id":"1124906464","pubTimestamp":1624936236,"share":"https://ttm.financial/m/news/1124906464?lang=&edition=fundamental","pubTime":"2021-06-29 11:10","market":"us","language":"en","title":"CVRx Pursues $100 Million U.S. IPO Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1124906464","media":"seekingalpha","summary":"Summary\n\nCVRx has filed to raise $100 million in a U.S. IPO of its common stock.\nThe firm is commerc","content":"<p>Summary</p>\n<ul>\n <li>CVRx has filed to raise $100 million in a U.S. IPO of its common stock.</li>\n <li>The firm is commercializing a neuromodulation device for treating a certain type of heart failure condition.</li>\n <li>CVRX has rebounded from the negative effects of the COVID-19 pandemic but the IPO appears pricey, so I'll watch it from the sidelines.</li>\n <li>Looking for more investing ideas like this one? Get them exclusively at IPO Edge.</li>\n</ul>\n<p>CVRx (CVRX) has filed to raise $100 million in an IPO of its common stock, according to an S-1/Aregistration statement.</p>\n<p>The firm is commercializing a neurostimulation device to treat patients with systolic Heart failure symptoms.</p>\n<p>CVRX was negatively affected by the COVID-19 pandemic but has rebounded.</p>\n<p>However, the IPO appears pricey, so I'll watch it from the sidelines.</p>\n<p><b>Company and Technology</b></p>\n<p>Minneapolis, Minnesota-based CVRx was founded to develop its BAROSTIM device that sends persistent electrical pulses tobaroreceptors inside the wall of the carotid artery as a signal to the brain to modulate cardiovascular function.</p>\n<p>Management is headed by president and CEO NadimYaredwho has been with the firm since 2006 and was previously vice president and general manager of Medtronic Navigation.</p>\n<p>CVRx has received at least $330 million in equity investment from investors including Johnson &amp; Johnson, New Enterprise Associates, Cooperative Glide Healthcare, Vensana Capital, Action Potential Venture Capital and Treo Ventures.</p>\n<p><b>Customer Acquisition and Market</b></p>\n<p>The firm sells its BAROSTIM NEO to hospitals through its direct sales organizations in the U.S. and Germany and through distributors in other European countries.</p>\n<p>The firm saw a reduction in demand in 2020 due to the restriction of hospital access to patients with relevant conditions.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have risen as revenues have fluctuated, as the figures below indicate:</p>\n<table>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>155.9%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>160.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>97.6%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>(Source)</p>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.3x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>0.3</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.0</p></td>\n  </tr>\n </tbody>\n</table>\n<p>(Source)</p>\n<p>According to a 2016 marketresearch reportby Allied Market Research, the global market for neuromodulation is expected to reach $11.7 billion by 2022.</p>\n<p>This represents a forecast CAGR of 13.1% from 2016 to 2022.</p>\n<p>The main drivers for this expected growth are a growing geriatric population and a resulting increase in neurological disorders.</p>\n<p>Also, an increase in Alzheimer's and Parkinson's disease conditions also will likely add to demand.</p>\n<p><b>Financial Performance</b></p>\n<p>CVRx’s recent financial results can be summarized as follows:</p>\n<ul>\n <li><p>Rebounding topline revenue growth</p></li>\n <li><p>Increasing gross profit but uneven gross margin</p></li>\n <li><p>Growing operating losses</p></li>\n <li><p>Increasing cash used in operations</p></li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<table>\n <tbody>\n  <tr>\n   <td><p><b>Total Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Total Revenue</p></td>\n   <td><p>% Variance vs. Prior</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ 2,860,000</p></td>\n   <td><p>66.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ 6,053,000</p></td>\n   <td><p>-3.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ 6,257,000</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Gross Profit (Loss)</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Gross Profit (Loss)</p></td>\n   <td><p>% Variance vs. Prior</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ 1,993,000</p></td>\n   <td><p>55.0%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ 4,613,000</p></td>\n   <td><p>0.9%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ 4,574,000</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Gross Margin</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Gross Margin</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>69.69%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>76.21%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>73.10%</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Operating Profit (Loss)</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Operating Profit (Loss)</p></td>\n   <td><p>Operating Margin</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ (4,217,000)</p></td>\n   <td><p>-147.4%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ (11,514,000)</p></td>\n   <td><p>-190.2%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ (10,194,000)</p></td>\n   <td><p>-162.9%</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Net Income (Loss)</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Net Income (Loss)</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ (8,627,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ (14,109,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ (14,633,000)</p></td>\n  </tr>\n  <tr>\n   <td><p><b>Cash Flow From Operations</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Cash Flow From Operations</p></td>\n  </tr>\n  <tr>\n   <td><p>Three Mos. Ended March 31, 2021</p></td>\n   <td><p>$ (5,038,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>$ (16,096,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>$ (12,785,000)</p></td>\n  </tr>\n  <tr>\n   <td><p>(Glossary Of Terms)</p></td>\n  </tr>\n </tbody>\n</table>\n<p>(Source)</p>\n<p>As of March 31, 2021, CVRx had $54 million in cash and $32.1 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended March 31, 2021, was negative ($16.9 million).</p>\n<p><b>IPO Details</b></p>\n<p>CVRx intends to raise $100 million in gross proceeds from an IPO of its common stock, offering 6.25 million shares at a proposed midpoint price of $16.00 per share.</p>\n<p>No existing shareholders have indicated an interest to purchase shares at the IPO price.</p>\n<p>Assuming a successful IPO, the company’s enterprise value at IPO would approximate $170.6 million, excluding the effects of underwriter over-allotment options.</p>\n<p>Excluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximately 33.7%. A figure under 10% is generally considered a ‘low float’ stock which can be subject to significant price volatility.</p>\n<p>Management says it will use the net proceeds from the IPO as follows:</p>\n<blockquote>\n Approximately $75.0 million to continue funding the expansion of our direct sales force and commercial organization related to BAROSTIM NEO in the U.S.;Approximately $12.0 million to fund research and development activities related to BAROSTIM Therapy; andThe remainder for working capital and general corporate purposes. (Source)\n</blockquote>\n<p>Management’s presentation of the company roadshow isavailable here.</p>\n<p>Listed bookrunners of the IPO are JPMorgan, Piper Sandler, William Blair and Canaccord Genuity.</p>\n<p><b>Valuation Metrics</b></p>\n<p>Below is a table of relevant capitalization and valuation figures for the company:</p>\n<table>\n <tbody>\n  <tr>\n   <td><p><b>Measure [TTM]</b></p></td>\n   <td><p><b>Amount</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Market Capitalization at IPO</p></td>\n   <td><p>$296,717,728</p></td>\n  </tr>\n  <tr>\n   <td><p>Enterprise Value</p></td>\n   <td><p>$170,592,728</p></td>\n  </tr>\n  <tr>\n   <td><p>Price / Sales</p></td>\n   <td><p>41.24</p></td>\n  </tr>\n  <tr>\n   <td><p>EV / Revenue</p></td>\n   <td><p>23.71</p></td>\n  </tr>\n  <tr>\n   <td><p>EV / EBITDA</p></td>\n   <td><p>-13.70</p></td>\n  </tr>\n  <tr>\n   <td><p>Earnings Per Share</p></td>\n   <td><p>-$0.97</p></td>\n  </tr>\n  <tr>\n   <td><p>Float To Outstanding Shares Ratio</p></td>\n   <td><p>33.70%</p></td>\n  </tr>\n  <tr>\n   <td><p>Proposed IPO Midpoint Price per Share</p></td>\n   <td><p>$16.00</p></td>\n  </tr>\n  <tr>\n   <td><p>Net Free Cash Flow</p></td>\n   <td><p>-$16,946,000</p></td>\n  </tr>\n  <tr>\n   <td><p>Free Cash Flow Yield Per Share</p></td>\n   <td><p>-5.71%</p></td>\n  </tr>\n  <tr>\n   <td><p>Revenue Growth Rate</p></td>\n   <td><p>66.47%</p></td>\n  </tr>\n  <tr>\n   <td><p>(Glossary Of Terms)</p></td>\n  </tr>\n </tbody>\n</table>\n<p>(Source)</p>\n<p><b>Commentary</b></p>\n<p>CVRx is seeking public investment capital for its continued commercialization efforts.</p>\n<p>The company’s financials show the negative effects of the COVID-19 pandemic on its revenue trajectory in 2020 as hospitals cut back on patient access to its products.</p>\n<p>Revenue growth and gross profit appears to have rebounded significantly in Q1 2021, although some of this growth may represent pent-up demand and may not necessarily be representative of a more sustainable growth path going forward.</p>\n<p>Free cash flow for the twelve months ended March 31, 2021, was negative ($16.9 million).</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue grew sharply in 2020 as revenue growth stalled during that period; its Selling, G&amp;A efficiency rate has since increased to 0.3x in Q1 2021.</p>\n<p>The market opportunity for providing neuromodulation approaches to heart failure are significant and the firm appears well positioned to take advantage of a growing elderly patient population as the U.S. geriatric population grows substantially over the coming years.</p>\n<p>JPMorgan is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 36.8% since their IPO. This is a mid-tier performance for all major underwriters during the period.</p>\n<p>The primary risk to the company’s outlook is the reimbursement process and penetration, both within the U.S. and internationally, which varies greatly from region to region.</p>\n<p>As for valuation, management is asking investors to pay an EV/revenue multiple of 23.7x, which appears to be priced for perfection, especially so soon after its sales were negatively affected by the pandemic.</p>\n<p>While CVRx will likely have an impressive growth year in 2021, paying nearly 24x trailing EV/revenue and 41x on a price/sales multiple is excessive in my view.</p>\n<p>Expected IPO Pricing Date: June 29, 2021</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVRx Pursues $100 Million U.S. IPO Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVRx Pursues $100 Million U.S. IPO Plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 11:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4436978-cvrx-pursues-100-million-us-ipo-plan><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nCVRx has filed to raise $100 million in a U.S. IPO of its common stock.\nThe firm is commercializing a neuromodulation device for treating a certain type of heart failure condition.\nCVRX has ...</p>\n\n<a href=\"https://seekingalpha.com/article/4436978-cvrx-pursues-100-million-us-ipo-plan\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CVRX":"CVRx, Inc."},"source_url":"https://seekingalpha.com/article/4436978-cvrx-pursues-100-million-us-ipo-plan","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1124906464","content_text":"Summary\n\nCVRx has filed to raise $100 million in a U.S. IPO of its common stock.\nThe firm is commercializing a neuromodulation device for treating a certain type of heart failure condition.\nCVRX has rebounded from the negative effects of the COVID-19 pandemic but the IPO appears pricey, so I'll watch it from the sidelines.\nLooking for more investing ideas like this one? Get them exclusively at IPO Edge.\n\nCVRx (CVRX) has filed to raise $100 million in an IPO of its common stock, according to an S-1/Aregistration statement.\nThe firm is commercializing a neurostimulation device to treat patients with systolic Heart failure symptoms.\nCVRX was negatively affected by the COVID-19 pandemic but has rebounded.\nHowever, the IPO appears pricey, so I'll watch it from the sidelines.\nCompany and Technology\nMinneapolis, Minnesota-based CVRx was founded to develop its BAROSTIM device that sends persistent electrical pulses tobaroreceptors inside the wall of the carotid artery as a signal to the brain to modulate cardiovascular function.\nManagement is headed by president and CEO NadimYaredwho has been with the firm since 2006 and was previously vice president and general manager of Medtronic Navigation.\nCVRx has received at least $330 million in equity investment from investors including Johnson & Johnson, New Enterprise Associates, Cooperative Glide Healthcare, Vensana Capital, Action Potential Venture Capital and Treo Ventures.\nCustomer Acquisition and Market\nThe firm sells its BAROSTIM NEO to hospitals through its direct sales organizations in the U.S. and Germany and through distributors in other European countries.\nThe firm saw a reduction in demand in 2020 due to the restriction of hospital access to patients with relevant conditions.\nSelling, G&A expenses as a percentage of total revenue have risen as revenues have fluctuated, as the figures below indicate:\n\n\n\nSelling, G&A\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nThree Mos. Ended March 31, 2021\n155.9%\n\n\n2020\n160.5%\n\n\n2019\n97.6%\n\n\n\n(Source)\nThe Selling, G&A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&A spend, rose to 0.3x in the most recent reporting period, as shown in the table below:\n\n\n\nSelling, G&A\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nThree Mos. Ended March 31, 2021\n0.3\n\n\n2020\n0.0\n\n\n\n(Source)\nAccording to a 2016 marketresearch reportby Allied Market Research, the global market for neuromodulation is expected to reach $11.7 billion by 2022.\nThis represents a forecast CAGR of 13.1% from 2016 to 2022.\nThe main drivers for this expected growth are a growing geriatric population and a resulting increase in neurological disorders.\nAlso, an increase in Alzheimer's and Parkinson's disease conditions also will likely add to demand.\nFinancial Performance\nCVRx’s recent financial results can be summarized as follows:\n\nRebounding topline revenue growth\nIncreasing gross profit but uneven gross margin\nGrowing operating losses\nIncreasing cash used in operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\n\n\nTotal Revenue\n\n\nPeriod\nTotal Revenue\n% Variance vs. Prior\n\n\nThree Mos. Ended March 31, 2021\n$ 2,860,000\n66.5%\n\n\n2020\n$ 6,053,000\n-3.3%\n\n\n2019\n$ 6,257,000\n\n\nGross Profit (Loss)\n\n\nPeriod\nGross Profit (Loss)\n% Variance vs. Prior\n\n\nThree Mos. Ended March 31, 2021\n$ 1,993,000\n55.0%\n\n\n2020\n$ 4,613,000\n0.9%\n\n\n2019\n$ 4,574,000\n\n\nGross Margin\n\n\nPeriod\nGross Margin\n\n\nThree Mos. Ended March 31, 2021\n69.69%\n\n\n2020\n76.21%\n\n\n2019\n73.10%\n\n\nOperating Profit (Loss)\n\n\nPeriod\nOperating Profit (Loss)\nOperating Margin\n\n\nThree Mos. Ended March 31, 2021\n$ (4,217,000)\n-147.4%\n\n\n2020\n$ (11,514,000)\n-190.2%\n\n\n2019\n$ (10,194,000)\n-162.9%\n\n\nNet Income (Loss)\n\n\nPeriod\nNet Income (Loss)\n\n\nThree Mos. Ended March 31, 2021\n$ (8,627,000)\n\n\n2020\n$ (14,109,000)\n\n\n2019\n$ (14,633,000)\n\n\nCash Flow From Operations\n\n\nPeriod\nCash Flow From Operations\n\n\nThree Mos. Ended March 31, 2021\n$ (5,038,000)\n\n\n2020\n$ (16,096,000)\n\n\n2019\n$ (12,785,000)\n\n\n(Glossary Of Terms)\n\n\n\n(Source)\nAs of March 31, 2021, CVRx had $54 million in cash and $32.1 million in total liabilities.\nFree cash flow during the twelve months ended March 31, 2021, was negative ($16.9 million).\nIPO Details\nCVRx intends to raise $100 million in gross proceeds from an IPO of its common stock, offering 6.25 million shares at a proposed midpoint price of $16.00 per share.\nNo existing shareholders have indicated an interest to purchase shares at the IPO price.\nAssuming a successful IPO, the company’s enterprise value at IPO would approximate $170.6 million, excluding the effects of underwriter over-allotment options.\nExcluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximately 33.7%. A figure under 10% is generally considered a ‘low float’ stock which can be subject to significant price volatility.\nManagement says it will use the net proceeds from the IPO as follows:\n\n Approximately $75.0 million to continue funding the expansion of our direct sales force and commercial organization related to BAROSTIM NEO in the U.S.;Approximately $12.0 million to fund research and development activities related to BAROSTIM Therapy; andThe remainder for working capital and general corporate purposes. (Source)\n\nManagement’s presentation of the company roadshow isavailable here.\nListed bookrunners of the IPO are JPMorgan, Piper Sandler, William Blair and Canaccord Genuity.\nValuation Metrics\nBelow is a table of relevant capitalization and valuation figures for the company:\n\n\n\nMeasure [TTM]\nAmount\n\n\nMarket Capitalization at IPO\n$296,717,728\n\n\nEnterprise Value\n$170,592,728\n\n\nPrice / Sales\n41.24\n\n\nEV / Revenue\n23.71\n\n\nEV / EBITDA\n-13.70\n\n\nEarnings Per Share\n-$0.97\n\n\nFloat To Outstanding Shares Ratio\n33.70%\n\n\nProposed IPO Midpoint Price per Share\n$16.00\n\n\nNet Free Cash Flow\n-$16,946,000\n\n\nFree Cash Flow Yield Per Share\n-5.71%\n\n\nRevenue Growth Rate\n66.47%\n\n\n(Glossary Of Terms)\n\n\n\n(Source)\nCommentary\nCVRx is seeking public investment capital for its continued commercialization efforts.\nThe company’s financials show the negative effects of the COVID-19 pandemic on its revenue trajectory in 2020 as hospitals cut back on patient access to its products.\nRevenue growth and gross profit appears to have rebounded significantly in Q1 2021, although some of this growth may represent pent-up demand and may not necessarily be representative of a more sustainable growth path going forward.\nFree cash flow for the twelve months ended March 31, 2021, was negative ($16.9 million).\nSelling, G&A expenses as a percentage of total revenue grew sharply in 2020 as revenue growth stalled during that period; its Selling, G&A efficiency rate has since increased to 0.3x in Q1 2021.\nThe market opportunity for providing neuromodulation approaches to heart failure are significant and the firm appears well positioned to take advantage of a growing elderly patient population as the U.S. geriatric population grows substantially over the coming years.\nJPMorgan is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 36.8% since their IPO. This is a mid-tier performance for all major underwriters during the period.\nThe primary risk to the company’s outlook is the reimbursement process and penetration, both within the U.S. and internationally, which varies greatly from region to region.\nAs for valuation, management is asking investors to pay an EV/revenue multiple of 23.7x, which appears to be priced for perfection, especially so soon after its sales were negatively affected by the pandemic.\nWhile CVRx will likely have an impressive growth year in 2021, paying nearly 24x trailing EV/revenue and 41x on a price/sales multiple is excessive in my view.\nExpected IPO Pricing Date: June 29, 2021","news_type":1},"isVote":1,"tweetType":1,"viewCount":432,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}